K Number
K970771
Device Name
SULLIVAN AUTOSET PORTABLE II NASAL CPAP SYSTEM
Manufacturer
Date Cleared
1997-06-20

(109 days)

Product Code
Regulation Number
868.5905
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
TREATMENT OF OBSTRUCTIVE SLEEP APNEA IN ADULT PATIENTS
Device Description
SULLIVAN® AutoSet™ Portable II Nasal CPAP System
More Information

Not Found

Not Found

No
The summary explicitly states "Mentions AI, DNN, or ML: Not Found" and provides no other information suggesting the use of these technologies.

Yes
The device is described as a "Nasal CPAP System" for the "TREATMENT OF OBSTRUCTIVE SLEEP APNEA IN ADULT PATIENTS," which clearly indicates a therapeutic purpose.

No
Explanation: The device is described as a "Nasal CPAP System" for the "TREATMENT OF OBSTRUCTIVE SLEEP APNEA". CPAP (Continuous Positive Airway Pressure) systems are therapeutic devices, not diagnostic ones.

No

The device description explicitly states "Nasal CPAP System," which is a hardware-based medical device used for treating sleep apnea. The summary does not mention any software-only components or functions.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is "TREATMENT OF OBSTRUCTIVE SLEEP APNEA IN ADULT PATIENTS". This describes a therapeutic intervention, not a diagnostic test performed on samples taken from the body.
  • Device Description: The device is a "Nasal CPAP System". CPAP (Continuous Positive Airway Pressure) devices are used to deliver air pressure to keep airways open during sleep, which is a treatment for sleep apnea.
  • Lack of IVD Characteristics: The description does not mention any of the typical characteristics of an IVD, such as:
    • Analyzing biological samples (blood, urine, tissue, etc.)
    • Providing diagnostic information about a disease or condition
    • Using reagents or assays

Therefore, the SULLIVAN® AutoSet™ Portable II Nasal CPAP System is a therapeutic device used for the treatment of sleep apnea, not an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

TREATMENT OF OBSTRUCTIVE SLEEP APNEA IN ADULT PATIENTS

Product codes

73 BZD

Device Description

SULLIVAN® AutoSet™ Portable II Nasal CPAP System

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

ADULT

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Not Found

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

Not Found

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 868.5905 Noncontinuous ventilator (IPPB).

(a)
Identification. A noncontinuous ventilator (intermittent positive pressure breathing-IPPB) is a device intended to deliver intermittently an aerosol to a patient's lungs or to assist a patient's breathing.(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features the department's emblem, which is a stylized human figure with three faces in profile, surrounded by the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement. The emblem is simple and modern, and the text is clear and easy to read.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Dr. Michael D. Hallett ResMed Corp. 5744 Pacific Center Blvd., Suite 311 San Diego, California 92121

JUN 20 1997

Re: K970771 SULLIVAN® AutoSet Portable II Nasal CPAP System Requlatory Class: II (two) Product Code: 73 BZD Dated: May 29, 1997 Received: June 2, 1997

Dear Dr. Hallett:

We have reviewed your Section 510 (k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, qood manufacturing practice, labeling, and prohibitions aqainst misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP 2 inspections, the Food and Drug Administration (FDA) will verify such Failure to comply with the GMP regulation may result in assumptions. regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

1

Page 2 - Dr. Michael D. Hallett

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,
Thomas J. Callahon

Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

2.3 Indications for Use

ResMed Ltd

510(k) Number (if known):

SULLIVAN® AutoSet™ Portable II Nasal CPAP System Device Name:

Indications For Use:

TREATMENT OF OBSTRUCTIVE SLEEP APNEA IN ADULT PATIENTS

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Christy Forumin
(Division Sign-Off)
Division of Cardiovascular, Respiratory, and Neurological Devices
510(k) NumberK970771
Prescription UseOROver-The-Counter Use
(Per 21 CFR 801.109)

(Optional Format 1-2-96)